|
US3687808A
(en)
|
1969-08-14 |
1972-08-29 |
Univ Leland Stanford Junior |
Synthetic polynucleotides
|
|
US4469863A
(en)
|
1980-11-12 |
1984-09-04 |
Ts O Paul O P |
Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
|
|
US5023243A
(en)
|
1981-10-23 |
1991-06-11 |
Molecular Biosystems, Inc. |
Oligonucleotide therapeutic agent and method of making same
|
|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
|
US5034506A
(en)
|
1985-03-15 |
1991-07-23 |
Anti-Gene Development Group |
Uncharged morpholino-based polymers having achiral intersubunit linkages
|
|
JP2828642B2
(ja)
|
1987-06-24 |
1998-11-25 |
ハワード フローレイ インスティテュト オブ イクスペリメンタル フィジオロジー アンド メディシン |
ヌクレオシド誘導体
|
|
US4924624A
(en)
|
1987-10-22 |
1990-05-15 |
Temple University-Of The Commonwealth System Of Higher Education |
2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
|
|
US5278302A
(en)
|
1988-05-26 |
1994-01-11 |
University Patents, Inc. |
Polynucleotide phosphorodithioates
|
|
US5216141A
(en)
|
1988-06-06 |
1993-06-01 |
Benner Steven A |
Oligonucleotide analogs containing sulfur linkages
|
|
US5328470A
(en)
|
1989-03-31 |
1994-07-12 |
The Regents Of The University Of Michigan |
Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
|
|
US5134066A
(en)
|
1989-08-29 |
1992-07-28 |
Monsanto Company |
Improved probes using nucleosides containing 3-dezauracil analogs
|
|
US5591722A
(en)
|
1989-09-15 |
1997-01-07 |
Southern Research Institute |
2'-deoxy-4'-thioribonucleosides and their antiviral activity
|
|
US5399676A
(en)
|
1989-10-23 |
1995-03-21 |
Gilead Sciences |
Oligonucleotides with inverted polarity
|
|
US5264562A
(en)
|
1989-10-24 |
1993-11-23 |
Gilead Sciences, Inc. |
Oligonucleotide analogs with novel linkages
|
|
JPH05504552A
(ja)
|
1989-10-24 |
1993-07-15 |
ギリアド サイエンシズ，インコーポレイテッド |
２’位が改変されたオリゴヌクレオチド
|
|
JP3056782B2
(ja)
|
1989-11-03 |
2000-06-26 |
ヴァンダービルト ユニバーシティ |
標的器官内での遺伝子の発現用医薬組成物
|
|
US5177198A
(en)
|
1989-11-30 |
1993-01-05 |
University Of N.C. At Chapel Hill |
Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
|
|
US5459255A
(en)
|
1990-01-11 |
1995-10-17 |
Isis Pharmaceuticals, Inc. |
N-2 substituted purines
|
|
US5587361A
(en)
|
1991-10-15 |
1996-12-24 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having phosphorothioate linkages of high chiral purity
|
|
US5670633A
(en)
|
1990-01-11 |
1997-09-23 |
Isis Pharmaceuticals, Inc. |
Sugar modified oligonucleotides that detect and modulate gene expression
|
|
US5587470A
(en)
|
1990-01-11 |
1996-12-24 |
Isis Pharmaceuticals, Inc. |
3-deazapurines
|
|
US5646265A
(en)
|
1990-01-11 |
1997-07-08 |
Isis Pharmceuticals, Inc. |
Process for the preparation of 2'-O-alkyl purine phosphoramidites
|
|
US5578718A
(en)
|
1990-01-11 |
1996-11-26 |
Isis Pharmaceuticals, Inc. |
Thiol-derivatized nucleosides
|
|
US5212295A
(en)
|
1990-01-11 |
1993-05-18 |
Isis Pharmaceuticals |
Monomers for preparation of oligonucleotides having chiral phosphorus linkages
|
|
US5506351A
(en)
|
1992-07-23 |
1996-04-09 |
Isis Pharmaceuticals |
Process for the preparation of 2'-O-alkyl guanosine and related compounds
|
|
US5321131A
(en)
|
1990-03-08 |
1994-06-14 |
Hybridon, Inc. |
Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
|
|
US5470967A
(en)
|
1990-04-10 |
1995-11-28 |
The Dupont Merck Pharmaceutical Company |
Oligonucleotide analogs with sulfamate linkages
|
|
US5489677A
(en)
|
1990-07-27 |
1996-02-06 |
Isis Pharmaceuticals, Inc. |
Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
|
|
US5610289A
(en)
|
1990-07-27 |
1997-03-11 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogues
|
|
US5602240A
(en)
|
1990-07-27 |
1997-02-11 |
Ciba Geigy Ag. |
Backbone modified oligonucleotide analogs
|
|
US5218105A
(en)
|
1990-07-27 |
1993-06-08 |
Isis Pharmaceuticals |
Polyamine conjugated oligonucleotides
|
|
US5541307A
(en)
|
1990-07-27 |
1996-07-30 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogs and solid phase synthesis thereof
|
|
US5608046A
(en)
|
1990-07-27 |
1997-03-04 |
Isis Pharmaceuticals, Inc. |
Conjugated 4'-desmethyl nucleoside analog compounds
|
|
US6262241B1
(en)
|
1990-08-13 |
2001-07-17 |
Isis Pharmaceuticals, Inc. |
Compound for detecting and modulating RNA activity and gene expression
|
|
US5214134A
(en)
|
1990-09-12 |
1993-05-25 |
Sterling Winthrop Inc. |
Process of linking nucleosides with a siloxane bridge
|
|
CA2027872A1
(en)
|
1990-10-17 |
1992-04-18 |
Jack Sklarchuck |
Method for preparing lead-acid battery plates
|
|
US5539082A
(en)
|
1993-04-26 |
1996-07-23 |
Nielsen; Peter E. |
Peptide nucleic acids
|
|
JP2823959B2
(ja)
|
1991-10-24 |
1998-11-11 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
改良された取り込みおよびその他の性質を持つ誘導化オリゴヌクレオチド
|
|
US5594121A
(en)
|
1991-11-07 |
1997-01-14 |
Gilead Sciences, Inc. |
Enhanced triple-helix and double-helix formation with oligomers containing modified purines
|
|
US5359044A
(en)
|
1991-12-13 |
1994-10-25 |
Isis Pharmaceuticals |
Cyclobutyl oligonucleotide surrogates
|
|
US20030206887A1
(en)
|
1992-05-14 |
2003-11-06 |
David Morrissey |
RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
|
|
EP0577558A2
(de)
|
1992-07-01 |
1994-01-05 |
Ciba-Geigy Ag |
Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte
|
|
NL9201440A
(nl)
|
1992-08-11 |
1994-03-01 |
Univ Leiden |
Triantennaire clusterglycosiden, hun bereiding en toepassing.
|
|
GB9304618D0
(en)
|
1993-03-06 |
1993-04-21 |
Ciba Geigy Ag |
Chemical compounds
|
|
WO1994022891A1
(en)
|
1993-03-31 |
1994-10-13 |
Sterling Winthrop Inc. |
Oligonucleotides with amide linkages replacing phosphodiester linkages
|
|
JP3278981B2
(ja)
|
1993-06-23 |
2002-04-30 |
株式会社日立製作所 |
半導体メモリ
|
|
US5571902A
(en)
|
1993-07-29 |
1996-11-05 |
Isis Pharmaceuticals, Inc. |
Synthesis of oligonucleotides
|
|
US5519134A
(en)
|
1994-01-11 |
1996-05-21 |
Isis Pharmaceuticals, Inc. |
Pyrrolidine-containing monomers and oligomers
|
|
US5596091A
(en)
|
1994-03-18 |
1997-01-21 |
The Regents Of The University Of California |
Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
|
|
US5554746A
(en)
|
1994-05-16 |
1996-09-10 |
Isis Pharmaceuticals, Inc. |
Lactam nucleic acids
|
|
US5597909A
(en)
|
1994-08-25 |
1997-01-28 |
Chiron Corporation |
Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
|
|
US6166197A
(en)
|
1995-03-06 |
2000-12-26 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
|
|
US5856459A
(en)
|
1995-06-06 |
1999-01-05 |
Hybridon, Inc. |
Oligonucleotides specific for hepatitis B virus
|
|
US5985662A
(en)
|
1995-07-13 |
1999-11-16 |
Isis Pharmaceuticals Inc. |
Antisense inhibition of hepatitis B virus replication
|
|
US6127533A
(en)
|
1997-02-14 |
2000-10-03 |
Isis Pharmaceuticals, Inc. |
2'-O-aminooxy-modified oligonucleotides
|
|
US6172209B1
(en)
|
1997-02-14 |
2001-01-09 |
Isis Pharmaceuticals Inc. |
Aminooxy-modified oligonucleotides and methods for making same
|
|
US6271358B1
(en)
|
1998-07-27 |
2001-08-07 |
Isis Pharmaceuticals, Inc. |
RNA targeted 2′-modified oligonucleotides that are conformationally preorganized
|
|
IL142490A0
(en)
|
1998-10-09 |
2002-03-10 |
Ingene Inc |
ENZYMATIC SYNTHESIS OF ssDNA
|
|
US5977341A
(en)
|
1998-11-20 |
1999-11-02 |
Isis Pharmaceuticals Inc. |
Antisense modulation of inhibitor-kappa B kinase-beta expression
|
|
WO2000053722A2
(en)
|
1999-03-10 |
2000-09-14 |
Phogen Limited |
Delivery of nucleic acids and proteins to cells
|
|
EP1102785B1
(en)
|
1999-06-07 |
2013-02-13 |
Arrowhead Research Corporation |
COMPOSITIONS FOR DRUG DELIVERY USING pH SENSITIVE MOLECULES
|
|
US7019113B2
(en)
|
1999-06-07 |
2006-03-28 |
Mirus Bio Corporation |
Reversible modification of membrane interaction
|
|
US8202979B2
(en)
|
2002-02-20 |
2012-06-19 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
|
|
WO2003070918A2
(en)
|
2002-02-20 |
2003-08-28 |
Ribozyme Pharmaceuticals, Incorporated |
Rna interference by modified short interfering nucleic acid
|
|
US8273866B2
(en)
|
2002-02-20 |
2012-09-25 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
|
|
US20050032733A1
(en)
|
2001-05-18 |
2005-02-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
|
|
CA2442092A1
(en)
|
2001-03-26 |
2002-10-17 |
Ribozyme Pharmaceuticals, Inc. |
Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
|
|
AU2004266311B2
(en)
|
2001-05-18 |
2009-07-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
US9994853B2
(en)
|
2001-05-18 |
2018-06-12 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
|
US20060217331A1
(en)
|
2001-05-18 |
2006-09-28 |
Sirna Therapeutics, Inc. |
Chemically modified double stranded nucleic acid molecules that mediate RNA interference
|
|
US10590418B2
(en)
|
2001-07-23 |
2020-03-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for RNAi mediated inhibition of gene expression in mammals
|
|
US20030198627A1
(en)
|
2001-09-01 |
2003-10-23 |
Gert-Jan Arts |
siRNA knockout assay method and constructs
|
|
US7091186B2
(en)
|
2001-09-24 |
2006-08-15 |
Seattle Genetics, Inc. |
p-Amidobenzylethers in drug delivery agents
|
|
US6635428B2
(en)
|
2001-12-04 |
2003-10-21 |
Quest Diagnostics Investments Incorporated |
Oligonucleotides and methods for detecting hepatitis B viral nucleic acids
|
|
ATE443133T1
(de)
|
2002-02-01 |
2009-10-15 |
Life Technologies Corp |
Oligonukleotidzusammensetzungen mit verbesserter effizienz
|
|
EP1432724A4
(en)
|
2002-02-20 |
2006-02-01 |
Sirna Therapeutics Inc |
INTERFERENCE MEDIATION INHIBITION OF GENE RNA FROM MAP KINASE
|
|
US9181551B2
(en)
|
2002-02-20 |
2015-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
US8232383B2
(en)
|
2002-02-20 |
2012-07-31 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
EP3222724B1
(en)
|
2002-08-05 |
2018-10-31 |
Silence Therapeutics GmbH |
Further novel forms of interfering rna molecules
|
|
US7956176B2
(en)
|
2002-09-05 |
2011-06-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
US8604183B2
(en)
|
2002-11-05 |
2013-12-10 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
|
US7816337B2
(en)
|
2003-02-18 |
2010-10-19 |
Roche Madison Inc. |
Reversible attachment of a membrane active polymer to a polynucleotide
|
|
US20040162235A1
(en)
|
2003-02-18 |
2004-08-19 |
Trubetskoy Vladimir S. |
Delivery of siRNA to cells using polyampholytes
|
|
CN1257284C
(zh)
|
2003-03-05 |
2006-05-24 |
北京博奥生物芯片有限责任公司 |
一种体外阻断乙肝病毒表达的方法
|
|
US7750144B2
(en)
|
2003-06-02 |
2010-07-06 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of RNA silencing
|
|
EP1636385A4
(en)
|
2003-06-24 |
2010-06-02 |
Mirus Bio Corp |
INHIBITION OF GENE FUNCTION BY IN VIVO DISTRIBUTION OF GENE EXPRESSION INHIBITORS BASED ON POLYNUCLEOTIDES IN MAMMALIAN CELLS
|
|
WO2005021751A1
(en)
|
2003-09-01 |
2005-03-10 |
Patrick Arbuthnot |
A self-processing rna expression cassette
|
|
US20080311126A1
(en)
|
2004-01-12 |
2008-12-18 |
Genesense Technologies, Inc |
Antisense Oligonucleotides Directed to Ribonucleotide Reducatase R2 and Uses Thereof in Combination Therapies for the Treatment of Cancer
|
|
EP2514758B2
(en)
|
2004-03-15 |
2021-06-23 |
City of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
|
|
CN101052717A
(zh)
|
2004-05-11 |
2007-10-10 |
α基因株式会社 |
诱发rna干扰的多核苷酸以及使用该多核苷酸的基因表达抑制方法
|
|
ATE518954T1
(de)
|
2004-08-18 |
2011-08-15 |
Lorus Therapeutics Inc |
Kleine interferierende rna-moleküle gegen ribonukleotidreduktase und ihre verwendungen
|
|
CN101142316A
(zh)
|
2005-03-09 |
2008-03-12 |
牧岩生命工学研究所 |
小干扰rna和包含它的用于治疗乙型肝炎的药物组合物
|
|
ATE541928T1
(de)
|
2005-03-31 |
2012-02-15 |
Calando Pharmaceuticals Inc |
Inhibitoren der untereinheit 2 der ribonukleotidreduktase und ihre verwendungen
|
|
CN101426912A
(zh)
|
2005-08-17 |
2009-05-06 |
瑟纳治疗公司 |
介导rna干扰的化学修饰短干扰核酸分子
|
|
AU2006279454B2
(en)
|
2005-08-17 |
2011-12-15 |
Sirna Therapeutics, Inc. |
Chemically modified short interfering nucleic acid molecules that mediate rna interference
|
|
RU2418068C2
(ru)
|
2005-08-17 |
2011-05-10 |
Сирна Терапьютикс, Инк. |
Молекулы химически модифицированной короткой интерферирующей нуклеиновой кислоты, которые опосредуют интерференцию рнк
|
|
US20070197460A1
(en)
*
|
2005-11-01 |
2007-08-23 |
Alnylam Pharmaceuticals, Inc. |
Rnai inhibition of influenza virus replication
|
|
CN101024088A
(zh)
|
2006-02-20 |
2007-08-29 |
桂林医学院 |
抗乙型肝炎病毒微小核糖核酸干扰分子及其设计方法
|
|
KR101133799B1
(ko)
|
2006-08-18 |
2012-04-24 |
에프. 호프만-라 로슈 아게 |
폴리뉴클레오타이드의 생체내 전달을 위한 다가접합체
|
|
FR2909555B1
(fr)
|
2006-12-11 |
2009-01-30 |
Oreal |
Emulsion e/h a effet correcteur pour la peau
|
|
US8232257B2
(en)
|
2007-03-27 |
2012-07-31 |
University Of Iowa Research Foundation |
RNA interference mediated inactivation of hepatitis B virus in a subject
|
|
US8877917B2
(en)
|
2007-04-23 |
2014-11-04 |
Alnylam Pharmaceuticals, Inc. |
Glycoconjugates of RNA interference agents
|
|
EP2164965B1
(en)
|
2007-05-29 |
2013-09-11 |
University Of The Witwatersrand, Johannesburg |
A primary micro rna expression cassette
|
|
KR20100069679A
(ko)
|
2007-09-17 |
2010-06-24 |
재단법인 목암생명공학연구소 |
ＨＢＶ 또는 ＨＣＶ의 유전자 발현을 하향 조절하는 ｓｉＲＮＡ의 혈청 안정성 향상 및 면역 반응 저감 방법
|
|
EP2205740A2
(en)
|
2007-10-02 |
2010-07-14 |
Rxi Pharmaceuticals Corp. |
Tripartite rnai constructs
|
|
CA2910760C
(en)
|
2007-12-04 |
2019-07-09 |
Muthiah Manoharan |
Targeting lipids
|
|
WO2009126933A2
(en)
|
2008-04-11 |
2009-10-15 |
Alnylam Pharmaceuticals, Inc. |
Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
|
|
CN101322847A
(zh)
|
2008-06-23 |
2008-12-17 |
淮安市第四人民医院 |
基于siRNA池干扰的复合载体介导的抗乙肝病毒基因药物
|
|
US20100184841A1
(en)
|
2008-12-18 |
2010-07-22 |
Dicerna Pharmaceuticals, Inc. |
Extended dicer substrate agents and methods for the specific inhibition of gene expression
|
|
WO2010093788A2
(en)
|
2009-02-11 |
2010-08-19 |
Dicerna Pharmaceuticals, Inc. |
Multiplex dicer substrate rna interference molecules having joining sequences
|
|
EP2424877A4
(en)
|
2009-04-28 |
2013-01-02 |
Harvard College |
SUPRAGELADENE PROTEINS FOR CELL PENETRATION
|
|
US9012225B2
(en)
|
2009-05-05 |
2015-04-21 |
Miragen Therapeutics |
Lipophilic polynucleotide conjugates
|
|
US8207138B2
(en)
|
2009-05-19 |
2012-06-26 |
Medtronic, Inc. |
Methods and devices for improved efficiency of RNA delivery to cells
|
|
CA2766608C
(en)
|
2009-07-06 |
2018-06-19 |
F. Hoffmann-La Roche Ag |
Bi-specific digoxigenin binding antibodies
|
|
US20110152349A1
(en)
|
2009-12-18 |
2011-06-23 |
Anke Geick |
Compositions and methods for inhibiting expression of il-18 genes
|
|
WO2011100131A2
(en)
|
2010-01-28 |
2011-08-18 |
Alnylam Pharmacuticals, Inc. |
Monomers and oligonucleotides comprising cycloaddition adduct(s)
|
|
SI2539451T1
(sl)
|
2010-02-24 |
2016-04-29 |
Arrowhead Research Corporation |
Sestavki za ciljano dostavo sirna
|
|
EP2390327A1
(en)
|
2010-05-27 |
2011-11-30 |
Sylentis S.A. |
siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
|
|
HUE044815T2
(hu)
|
2010-08-17 |
2019-11-28 |
Sirna Therapeutics Inc |
Hepatitisz B vírus (HBV) génexpressziójának RNS-interferencia közvetített gátlása, rövid interferáló nukleinsav (SINS) alkalmazásával
|
|
US9290760B2
(en)
|
2010-09-15 |
2016-03-22 |
Alnylam Pharmaceuticals, Inc. |
Modified iRNA agents
|
|
CN101948834B
(zh)
|
2010-09-16 |
2012-07-04 |
山东大学 |
用于治疗HBV的siRNA
|
|
SI3124610T1
(sl)
|
2010-10-28 |
2019-08-30 |
Benitec Biopharma Limited |
Zdravljenje HBV
|
|
US9260471B2
(en)
|
2010-10-29 |
2016-02-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
|
|
US8501930B2
(en)
|
2010-12-17 |
2013-08-06 |
Arrowhead Madison Inc. |
Peptide-based in vivo siRNA delivery system
|
|
EP2658981B1
(en)
|
2010-12-29 |
2016-09-28 |
F.Hoffmann-La Roche Ag |
Small molecule conjugates for intracellular delivery of nucleic acids
|
|
UA118951C2
(uk)
|
2011-04-21 |
2019-04-10 |
Айоніс Фармасьютікалз, Інк. |
Модулювання експресії вірусу гепатиту b (hbv)
|
|
SMT201800152T1
(it)
|
2011-05-18 |
2018-05-02 |
Janssen Sciences Ireland Uc |
Derivati della chinazolina per il trattamento di infezioni virali e ulteriori malattie
|
|
WO2013003520A1
(en)
|
2011-06-30 |
2013-01-03 |
Arrowhead Research Corporation |
Compositions and methods for inhibiting gene expression of hepatitis b virus
|
|
TWI575070B
(zh)
|
2011-07-12 |
2017-03-21 |
傳斯堅公司 |
Ｈｂｖ聚合酶突變體
|
|
HK1199736A1
(en)
|
2011-08-26 |
2015-07-17 |
箭头研究公司 |
Poly(vinyl ester) polymers for in vivo nucleic acid delivery
|
|
IL284530B
(en)
|
2011-11-18 |
2022-07-01 |
Alnylam Pharmaceuticals Inc |
rnai factors, preparations and methods of using them for the treatment of transthyretin-related diseases
|
|
US8933047B2
(en)
|
2012-04-18 |
2015-01-13 |
Arrowhead Madison Inc. |
Poly(acrylate) polymers for in vivo nucleic acid delivery
|
|
WO2013159109A1
(en)
|
2012-04-20 |
2013-10-24 |
Isis Pharmaceuticals, Inc. |
Modulation of hepatitis b virus (hbv) expression
|
|
US9212363B2
(en)
|
2012-05-11 |
2015-12-15 |
City Of Hope |
RNAI molecules with non-watson crick pairing based on artificial mutation consensus sequences to counter escape mutations
|
|
GB2537000C
(en)
|
2012-05-25 |
2019-10-09 |
Univ California |
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
|
|
GB201215857D0
(en)
|
2012-09-05 |
2012-10-24 |
Sylentis Sau |
siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
|
|
CN103333890B
(zh)
|
2012-12-21 |
2015-04-15 |
厦门成坤生物技术有限公司 |
治疗乙型病毒性肝炎的rna干扰制剂
|
|
WO2015042447A1
(en)
|
2013-09-20 |
2015-03-26 |
Isis Pharmaceuticals, Inc. |
Targeted therapeutic nucleosides and their use
|
|
WO2015050871A2
(en)
|
2013-10-04 |
2015-04-09 |
Novartis Ag |
Organic compounds to treat hepatitis b virus
|
|
EP3137115B1
(en)
|
2014-05-01 |
2020-10-14 |
Ionis Pharmaceuticals, Inc. |
Method for synthesis of reactive conjugate clusters
|
|
CN104059916A
(zh)
|
2014-06-17 |
2014-09-24 |
湖北医药学院附属太和医院 |
乙肝病毒特异性的microRNA样siRNA序列及其用途
|
|
JOP20200115A1
(ar)
|
2014-10-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
|
|
JOP20200092A1
(ar)
|
2014-11-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
|
|
JP6557360B2
(ja)
*
|
2015-02-06 |
2019-08-07 |
エシティ・ハイジーン・アンド・ヘルス・アクチエボラグＥｓｓｉｔｙ Ｈｙｇｉｅｎｅ ａｎｄ Ｈｅａｌｔｈ Ａｋｔｉｅｂｏｌａｇ |
吸収性物品
|
|
US20170016000A1
(en)
*
|
2015-07-17 |
2017-01-19 |
Arcturus Therapeutics, Inc. |
Compositions and agents against hepatitis b virus and uses thereof
|
|
US20170137821A1
(en)
|
2015-07-17 |
2017-05-18 |
Arcturus Therapeutics, Inc. |
Molecules and agents for treating hepatitis b virus
|
|
WO2017019891A2
(en)
*
|
2015-07-29 |
2017-02-02 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing hepatitis b virus gene expression
|
|
AU2016306275A1
(en)
|
2015-08-07 |
2018-02-08 |
Arrowhead Pharmaceuticals, Inc. |
RNAi therapy for Hepatitis B virus infection
|
|
MA45478A
(fr)
|
2016-04-11 |
2019-02-20 |
Arbutus Biopharma Corp |
Compositions de conjugués d'acides nucléiques ciblés
|
|
JOP20170161A1
(ar)
|
2016-08-04 |
2019-01-30 |
Arrowhead Pharmaceuticals Inc |
عوامل RNAi للعدوى بفيروس التهاب الكبد ب
|
|
IL300869A
(en)
|
2016-09-02 |
2023-04-01 |
Arrowhead Pharmaceuticals Inc |
Ligands containing a targeting factor, preparations containing them and their uses
|
|
EA202091516A1
(ru)
|
2017-12-19 |
2020-11-03 |
Янссен Сайенсиз Айрлэнд Анлимитед Компани |
Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv)
|
|
EA202091517A1
(ru)
|
2017-12-19 |
2020-11-03 |
Янссен Сайенсиз Айрлэнд Анлимитед Компани |
Способы и устройство для доставки вакцин против вируса гепатита b (hbv)
|
|
EA202091513A1
(ru)
|
2017-12-19 |
2020-09-09 |
Янссен Сайенсиз Айрлэнд Анлимитед Компани |
Вакцины против вируса гепатита b (hbv) и их применение
|
|
TW201945003A
(zh)
|
2018-03-01 |
2019-12-01 |
愛爾蘭商健生科學愛爾蘭無限公司 |
２，４－二胺基喹唑啉衍生物及其醫學用途
|
|
PH12021551866A1
(en)
|
2019-02-07 |
2022-05-16 |
Arrowhead Pharmaceuticals Inc |
RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION
|
|
US20200332297A1
(en)
|
2019-04-18 |
2020-10-22 |
Janssen Pharmaceuticals, Inc. |
Combination therapy for treating hepatitis b virus infection
|
|
EP3969588A1
(en)
|
2019-05-13 |
2022-03-23 |
VIR Biotechnology, Inc. |
Compositions and methods for treating hepatitis b virus (hbv) infection
|
|
WO2020255007A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai
|
|
WO2022008613A1
(en)
|
2020-07-08 |
2022-01-13 |
Janssen Sciences Ireland Unlimited Company |
Rna replicon vaccines against hbv
|
|
TW202245809A
(zh)
|
2020-12-18 |
2022-12-01 |
美商詹森藥物公司 |
用於治療b型肝炎病毒感染之組合療法
|